MedicalDevice Licensing.com
Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register
About Us
Pharmalicensing - Partnering solutions for the life sciences
 
Our Products
Overview
Partnering Search
Company Profiling
Deal Negotiation
PL Intelligence
Reports
Comparison
 
PL Intelligence
Overview
Industry news
Deals review
Press releases
Articles
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire
Jobs
Forums
 
Contact Pharmalicensing
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing
is a division of
UTEK Europe Ltd
UTEK Corporation
Industry news

News of the day

Foamix Extends Collaboration with Galderma

Rehovot (Israel), November 3, 2009 -- Foamix Ltd, a global leader in the development of dermatological foam medications today announced that the company has extended its agreement with Galderma to develop an innovative medicated foam for an additional dermatological indication. This new treatment contains a novel drug for the therapy of certain skin diseases. more

Aeolus Pharmaceuticals' AEOL 10150 Protects Lungs Against Mustard Gas Exposure in Animal Studies

Mission Viejo, CA, October 7, 2009-- Aeolus Pharmaceuticals, Inc. (OTC Bulletin Board: AOLS) reported that researchers from National Jewish Health and Lovelace Respiratory Research Institute have completed a series of preliminary studies demonstrating that AEOL 10150 protects lungs from whole mustard gas exposure in rats. Data were presented at the Regional CounterACT Countermeasures Against Chemical Threats Conference in Albuquerque, NM. There are currently no effective treatments for mustard... more

Cipher announces enrollment of first patient in CIP-ISOTRETINOIN Phase III safety study

MISSISSAUGA, ON, Oct. 7 - Cipher Pharmaceuticals Inc. (TSX: DND) today announced that it has enrolled the first patient in its Phase III safety study of CIP-ISOTRETINOIN, the Company's novel, patented formulation of isotretinoin, which is used in the treatment of severe, nodular acne. more

Industry news search

Search the Pharmalicensing Industry news by keyword. Alternatively our advanced search allows you to query by category and therapeutic target.
 
Category Therapeutic target
 
To choose more then one item on the list hold CTRL button while selecting. To deselect items press CTRL button and deselect.

Recent news

To keep up to date with news from this category use our RSS Feed to keep up to date

Baxter Announces the Commercial Launch of HYLENEX at ACEP for use in Pediatric Rehydration
BOSTON - October 5, 2009-- Baxter International Inc. (NYSE: BAX) today announced the commercial launch of HYLENEX recombinant (hyaluronidase human injection) for use in pediatric rehydration at the 2009 American College...

Baxter Announces the Commercial Launch of HYLENEX at ACEP for Use in Pediatric Rehydration
October 05, 2009 -- BOSTON-- Baxter International Inc. (NYSE: BAX - News) today announced the commercial launch of HYLENEX recombinant (hyaluronidase human injection) for use in pediatric rehydration at the 2009...

Clients in focus...

Get the Flash Player to see this rotator.

Partnering and licensing intelligence in life sciences industry
Pharmalicensing Jobs 1
Stem Cell USA
Press releases: Pharmalicensing current industry press releases.

© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd UTEK Corporation All rights reserved. Terms and Conditions | Contact us